Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetes
血管化胰岛移植 NICHE 结合局部免疫抑制治疗 1 型糖尿病
基本信息
- 批准号:10656255
- 负责人:
- 金额:$ 69.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionAdverse effectsAffectAllogenicAnoxiaBeta CellBiodistributionBiometryBlood VesselsCaringCell SurvivalCell TherapyCell TransplantationCell physiologyCellsClinicalClinical ResearchCollaborationsCutaneousDataDiabetes MellitusDiseaseDrug Delivery SystemsDrug ImplantsDrug KineticsEncapsulatedEngraftmentEnvironmentEventExposure toFutureGoalsGraft RejectionHomingHormone secretionHydrogelsHypoxiaImmuneImmunosuppressionImmunosuppressive AgentsImplantIn SituInsulin-Dependent Diabetes MellitusIslets of LangerhansIslets of Langerhans TransplantationLifeLongevityLongitudinal StudiesMembraneMesenchymal Stem CellsMicrospheresModelingNanoporousNutrientOrganOrgan TransplantationOsmosisOxygenPatientsPharmaceutical PreparationsPharmacologic SubstancePhysiologicalPolymersPositioning AttributePublishingPumpQuality of lifeRegimenResearchRestSafetySiteSupporting CellSystemTechnologyTestingTherapeuticThinnessTissue EngineeringToxic effectTranslatingTransplantationTransplantation ImmunologyVascularizationWorkallotransplantclinical developmentclinical investigationclinical translationconditioningdesigndiabeticdiabetic ratefficacy evaluationengineered stem cellseuglycemiaflexibilityimmunoregulationimmunosuppressedimprovedinnovationisletislet allograftmanufactureminimally invasiveneovascularizationpharmacokinetic modelpost-transplantprototypescaffoldstem cellssubcutaneoustechnology platformtumor-immune system interactions
项目摘要
Cell encapsulation technologies are poised to improve conventional islet transplantation to more effectively
manage type I diabetes. Currently, lifelong whole-body immunosuppression is administered to avoid immune
rejection of the transplant, despite the associated life-threatening adverse effects. Clinical studies reveal that
transplants eventually fail due to lack of vascular support for nutrients and oxygen supply and host immune
rejection. To address all these critical needs and supported by preliminary studies, we propose the NICHE, an
innovative subcutaneous vascularized encapsulation system with local elution of immunosuppressants to protect
transplanted cells from immune rejection. The NICHE presents dual transcutaneously refillable reservoirs, for
drug and cells, respectively, separated by a nanoporous membrane. Local immunosuppressant delivery confines
drugs to the graft site where immune attack occurs, minimizing exposure to the rest of the body, thus avoiding
systemic immunosuppression and associated adverse effects. The NICHE cell reservoir is fully vascularized with
functional vessels, recreating an ideal physiological environment conducive for maintaining long-term viability
and function of transplanted cells. We hypothesize that the NICHE will provide a vascularized environment
with local immunosuppressant delivery for successful long-term islet engraftment to restore euglycemia
in diabetic hosts. In aim 1, we will study the ability of mesenchymal stem cells to induce vascularization within
the NICHE as well as modulate the NICHE immune microenvironment to be conducive for islet transplantation
in diabetic rats. This will be followed in aim 2 by the biodistribution analysis of immunosuppressants locally eluted
in the NICHE and the assessment of immunomodulation and pharmacokinetics in diabetic rats. In aim 3, the
NICHE efficacy in providing a suitable environment for successful islet engraftment to restore euglycemia in
diabetic rats will be assessed over 1 year, in parallel to a longitudinal study of NICHE microenvironment
remodeling. The proposed studies are based on our team’s extensive expertise in implantable drug and cell
delivery systems, tissue engineering, research and clinical transplantation, transplant immunology, type 1
diabetes, as well as supportive preliminary data and previously published work. Importantly, the NICHE is
designed prioritizing clinical considerations of efficacy, safety and user acceptability. Transcutaneous cell and
drug refilling allow for ease of drug replenishment when needed, thus extending implant lifespan potentially for
the lifetime of patients. Further, the thin and compact size of the NICHE, which is smaller than the encapsulation
implants under clinical investigation, is favorable for user acceptability. Successful completion of the proposed
work will provide a broadly applicable encapsulation system with localized immunosuppressant delivery for long-
term protection of transplanted islets, as well as minimize adverse effects associated with immunosuppressive
drugs. This could translate to a clinical breakthrough for deployment of cell therapies beyond islets, including
stem cell-derived β cells, to treat diabetes as well as other diseases.
细胞封装技术有望提高传统胰岛移植的效率
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Emerging immunomodulatory strategies for cell therapeutics.
- DOI:10.1016/j.tibtech.2022.11.008
- 发表时间:2022-12
- 期刊:
- 影响因子:17.3
- 作者:C. Y. Chua;A. Jiang;Tatiane Eufrásio-da-Silva;A. Dolatshahi-Pirouz;R. Langer;G. Orive;A. Grattoni
- 通讯作者:C. Y. Chua;A. Jiang;Tatiane Eufrásio-da-Silva;A. Dolatshahi-Pirouz;R. Langer;G. Orive;A. Grattoni
Implantable niche with local immunosuppression for islet allotransplantation achieves type 1 diabetes reversal in rats.
具有局部免疫抑制的植入式生态裂市场,用于同种异体移植的胰岛,可实现大鼠的1型糖尿病逆转。
- DOI:10.1038/s41467-022-35629-z
- 发表时间:2022-12-26
- 期刊:
- 影响因子:16.6
- 作者:Paez-Mayorga, Jesus;Campa-Carranza, Jocelyn Nikita;Capuani, Simone;Hernandez, Nathanael;Liu, Hsuan-Chen;Chua, Corrine Ying Xuan;Pons-Faudoa, Fernanda Paola;Malgir, Gulsah;Alvarez, Bella;Niles, Jean A.;Argueta, Lissenya B.;Shelton, Kathryn A.;Kezar, Sarah;Nehete, Pramod N.;Berman, Dora M.;Willman, Melissa A.;Li, Xian C.;Ricordi, Camillo;Nichols, Joan E.;Gaber, A. Osama;Kenyon, Norma S.;Grattoni, Alessandro
- 通讯作者:Grattoni, Alessandro
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alessandro Grattoni其他文献
Alessandro Grattoni的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alessandro Grattoni', 18)}}的其他基金
Long-acting multi prevention implant for 2-year contraception and HIV PrEP
用于 2 年避孕和 HIV PrEP 的长效多重预防植入物
- 批准号:
10619811 - 财政年份:2023
- 资助金额:
$ 69.85万 - 项目类别:
Ultra-long Acting Transcutaneously Refillable Islatravir Nanofluidic Implant for HIV Pre-Exposure
用于 HIV 暴露前的超长效经皮可再填充 Islatravir 纳米流体植入物
- 批准号:
10605334 - 财政年份:2022
- 资助金额:
$ 69.85万 - 项目类别:
Vascularized NICHE with local immunosuppression for cell replacement for Type 1 diabetes
带有局部免疫抑制的血管化 NICHE 用于细胞替代治疗 1 型糖尿病
- 批准号:
10704182 - 财政年份:2022
- 资助金额:
$ 69.85万 - 项目类别:
Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetes
血管化胰岛移植 NICHE 结合局部免疫抑制治疗 1 型糖尿病
- 批准号:
10417410 - 财政年份:2022
- 资助金额:
$ 69.85万 - 项目类别:
Vascularized NICHE with local immunosuppression for cell replacement for Type 1 diabetes
带有局部免疫抑制的血管化 NICHE 用于细胞替代治疗 1 型糖尿病
- 批准号:
10511952 - 财政年份:2022
- 资助金额:
$ 69.85万 - 项目类别:
Ultra-long Acting Transcutaneously Refillable Islatravir Nanofluidic Implant for HIV Pre-Exposure
用于 HIV 暴露前的超长效经皮可再填充 Islatravir 纳米流体植入物
- 批准号:
10481727 - 财政年份:2022
- 资助金额:
$ 69.85万 - 项目类别:
A nanofluidic platform for tunable drug delivery
用于可调药物输送的纳米流体平台
- 批准号:
10093084 - 财政年份:2018
- 资助金额:
$ 69.85万 - 项目类别:
A novel nanochannel system for sustained delivery of Tenofovir Alafenamide Fumarate and Emtricitabine for HIV pre-exposure prophylaxis
一种新型纳米通道系统,用于持续递送富马酸替诺福韦艾拉酚胺和恩曲他滨,用于 HIV 暴露前预防
- 批准号:
9204020 - 财政年份:2016
- 资助金额:
$ 69.85万 - 项目类别:
A novel nanochannel system for sustained delivery of Tenofovir Alafenamide Fumarate and Emtricitabine for HIV pre-exposure prophylaxis
一种新型纳米通道系统,用于持续递送富马酸替诺福韦艾拉酚胺和恩曲他滨,用于 HIV 暴露前预防
- 批准号:
9300830 - 财政年份:2016
- 资助金额:
$ 69.85万 - 项目类别:
A tunable delivery platform for in vivo investigation of therapeutics
用于体内治疗研究的可调递送平台
- 批准号:
8755681 - 财政年份:2014
- 资助金额:
$ 69.85万 - 项目类别:
相似海外基金
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 69.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 69.85万 - 项目类别:
Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 69.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 69.85万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 69.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 69.85万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 69.85万 - 项目类别:
Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 69.85万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 69.85万 - 项目类别:
EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 69.85万 - 项目类别:
Standard Grant














{{item.name}}会员




